Vedanta Biosciences announces the Phase 3 RESTORATiVE303 study of VE303 for the prevention of recurrent C. difficile infection will continue as planned following protocol-specified interim analysis
Vedanta Biosciences announces the Phase 3 RESTORATiVE303 study of VE303 for the prevention of recurrent C. difficile infection will continue as planned following protocol-specified interim analysis
We use cookies to ensure that we give you the best experience on our website. Please visit carb-x.org/legal/ for more information. By clicking “Ok”, you consent to the use of all cookies.
Toggle navigation